Hepatitis C virus inhibitors

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

X is —O—, —C(O)—, —C(R A R B )—, NR A , or SO 2 ;

Y is —O—, —C(O)—, —C(R A R B )—, NR A , or SO 2 , such that one of X and Y is —O—, and the other of X and Y is other than —O—;

V is CH;

W is N;

V 1 is CH;

W 1 is N;

R A is H, halo, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, 4 to 6-membered monocyclic heterocycloalkyl, 5 or 6-membered monocyclic heteroaryl, 6 to 10-membered bicyclic heterocycloalkyl, C 6 -C 10 aryl, or —O—(C 1 -C 6 alkyl), wherein said C 3 -C 7 cycloalkyl group, said 4 to 6-membered monocyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group, said 6 to 10-membered bicyclic heterocycloalkyl, or said C 6 -C 10 aryl group, can be optionally substituted with up to 3 groups, which can be the same or different, and are selected from halo, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —O—C 1 -C 6 alkyl, —(C 1 -C 6 alkylene)-O—C 1 -C 6 alkyl and —O—(C 1 -C 6 haloalkyl);

R B is H, halo, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, 4 to 6-membered monocyclic heterocycloalkyl, 5 or 6-membered monocyclic heteroaryl, 6 to 10-membered bicyclic heterocycloalkyl, C 6 -C 10 aryl, or —O—(C 1 -C 6 alkyl), wherein said C 3 -C 7 cycloalkyl group, said 4 to 6-membered monocyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group, said 6 to 10-membered bicyclic heterocycloalkyl, or said C 6 -C 10 aryl group, can be optionally substituted with up to 3 groups, which can be the same or different, and are selected from halo, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —O—C 1 -C 6 alkyl, —(C 1 -C 6 alkylene)-O—C 1 -C 6 alkyl and —O—(C 1 -C 6 haloalkyl);

A is:

A′ is:

each occurrence of R 1 is H;

each occurrence of R 1A fis independently selected from H, and halo;

each occurrence of R 1B is H;

each occurrence of R 3 is independently H, —C(O)—C(R 4 ) 2 NHC(O)O—R 5 , —C(O)O—R 5 , C(O)NHR 5 or —C(O)—C(R 4 ) 2 NR′R 8 ;

each occurrence of R 4 is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, 4 to 8-membered monocyclic heterocycloalkyl, 6 to 10-membered bicyclic heterocycloalkyl and C 3 -C 7 cycloalkyl, wherein said 4 to 8-membered monocyclic heterocycloalkyl group, said 6 to 10-membered bicyclic heterocycloalkyl group, said C 6 -C 10 aryl group and said C 3 -C 7 cycloalkyl group can be optionally substituted with up to 5 groups, each independently selected from halo, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, —O—C 1 -C 6 alkyl, —N(R 6 ) 2 and —O—(C 1 -C 6 haloalkyl), and wherein said C 3 -C 7 cycloalkyl group can be optionally fused to a 4 to 6-membered monocyclic heterocycloalkyl group, and wherein said 4 to 8-membered monocyclic heterocycloalkyl group and said C 3 -C 7 cycloalkyl group can be substituted on a ring carbon atom with a spirocyclic C 3 -C 6 cycloalkyl group; and wherein said C 3 -C 7 cycloalkyl group can be substituted on a ring carbon atom with a spirocyclic 3 to 6-membered monocyclic heterocycloalkyl group, and wherein two R 4 groups, that are attached to a common carbon atom, together with the common carbon atom to which they are attached, can join to form a C 3 -C 7 cycloalkyl group;

each occurrence of R 5 is independently selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl and C 6 -C 10 aryl;

each occurrence of R 6 is independently selected from H, C 1 -C 6 alkyl and C 3 -C 7 cycloalkyl;

each occurrence of R 7 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, or phenyl, or R 7 and R 8 , together with the nitrogen atom to which they are attached, form a 3 to 6-membered monocyclic heterocycloalkyl group; and

each occurrence of R 8 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, or phenyl, or R 7 and R 8 , together with the nitrogen atom to which they are attached, form a 3 to 6-membered monocyclic heterocycloalkyl group.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A and A′ are each independently

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein each R 3 is independently H, —C(O)CH(CH(CH 3 ) 2 )(NHC(O)OCH 3 ), —C(O)OC(CH 3 ) 3 , C(O)NHC(CH 3 ) 3 ,

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 1A is independently H or fluoro.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R A and R B are independently H, halo, or —C 1 -C 6 alkyl.

6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R A and R B are independently H, fluoro, —CH 3 or —CH 2 CH 3 .

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 4 is independently H, —CH(CH 3 ) 3 ,

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 5 is independently CH 3 or —C(CH 3 ) 3 .

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 and R 8 are independently H or —C 1 -C 6 alkyl.

10. The compound of claim 1 which is

methyl [(1R)-1-({(2R)-2-[5-(9-{2-[(2R)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-7-oxo-7H-benzo[c]xanthen-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1S)-1-({(2S)-2-[5-(3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12-methyl-12H-benzo[a]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1S)-1-({(2S)-2-[5-(3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12-methyl-12H-benzo[a]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1S)-1-({(2S)-2-[5-(3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-7-methyl-7H-benzo[c]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1 S)-1-({(2S)-2-[5-(12-ethyl-3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12H-benzo[a]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1 S)-1-({(2S)-2-[5-(12-ethyl-3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12H-benzo[a]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1S)-1-({(2S)-2-[5-(3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12,12-dimethyl-12H-benzo[a]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1R)-1-({(2S)-2-[5-(12,12-diethyl-3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12H-benzo[a]xanthen-9-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1R)-1-({(2S)-2-[5-(12,12-diethyl-9-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12H-benzo[b]xanthen-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

dimethyl [(12-methyl-12H-benzo[a]xanthene-3,9-diyl)bis {1H-imidazole-5,2-diyl(2S)pyrrolidine-2,1-diyl[(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate,

dimethyl [(12-methyl-12H-benzo[a]xanthene-3,9-diyl)bis {1H-imidazole-5,2-diyl(2 S)pyrrolidine-2,1-diyl[(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate,

dimethyl [(12,12-dimethyl-12H-benzo[a]xanthene-3,9-diyl)bis{1H-imidazole-5,2-diyl(2 S)pyrrolidine-2,1-diyl[(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate,

dimethyl [(12-ethyl-12H-benzo[a]xanthene-3,9-diyl)bis{1H-imidazole-5,2-diyl(2 S)pyrrolidine-2,1-diyl[(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate,

dimethyl [(12-ethyl-12H-benzo[a]xanthene-3,9-diyl)bis{1H-imidazole-5,2-diyl(2 S)pyrrolidine-2,1-diyl[(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate,

methyl [(1R)-2-[(2R)-2-{5-[12,12-diethyl-9-(2-{(2R)-1-[(2S)-2-[(methoxycarbonyl)amino]-2-(tetrahydro-2H-pyran-4-yl)acetyl]pyrrolidin-2-yl}-1H-imidazol-5-yl)-12H-benzo[a]xanthen-3-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl]carbamate,

3-{2-[(2S,4R)-4-fluoropyrrolidin-2-yl]-1H-imidazol-5-yl}-9-{2-[(2S,4S)-4-fluoropyrrolidin-2-yl]-1H-imidazol-5-yl}-12H-benzo[a]xanthen-12-one,

6-fluoro-2,9-bis{2-[(2S,4S)-4-fluoropyrrolidin-2-yl]-1H-imidazol-5-yl}-12H-benzo[b]xanthen-12-one,

di-tert-butyl (2S,2′S)-2,2′-[(12-oxo-12H-benzo[a]xanthene-3,9-diyl)bis(1H-imidazole-5,2-diyl)]dipyrrolidine-1-carboxylate,

(2S,4R,2′S,4′S)-2,2′-[(12-oxo-12H-benzo[a]xanthene-3,9-diyl)bis(1H-imidazole-5,2-diyl)]bis(N-tert-butyl-4-fluoropyrrolidine-1-carboxamide),

di-tert-butyl (2S,4R,2′S,4′S)-2,2′-[(12-oxo-12H-benzo[a]xanthene-3,9-diyl)bis(1H-imidazole-5,2-diyl)]bis(4-fluoropyrrolidine-1-carboxylate),

methyl [(1S)-1-({(2S)-2-[5-(10-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12-oxo-12H-benzo[a]xanthen-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1S)-1-({(2S,4R)-4-fluoro-2-[5-(10-{2-[(2S,4R)-4-fluoro-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12-oxo-12H-benzo[a]xanthen-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

methyl [(1S)-1-({(2S,4R)-4-fluoro-2-[5-(9-{2-[(2S,4R)-4-fluoro-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12-oxo-12H-benzo[a]xanthen-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

dimethyl [(12-oxo-12H-benzo[a]xanthene-3,9-diyl)bis{1H-imidazole-5,2-diyl(2 S)pyrrolidine-2,1-diyl[(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate,

3,9-bis(2-{(2S,4R)-1-[(2R)-2-(diethylamino)-2-phenylacetyl]-4-fluoropyrrolidin-2-yl}-1H-imidazol-5-yl)-12H-benzo[a]xanthen-12-one,

dimethyl [(12-oxo-12H-benzo[a]xanthene-3,9-diyl)bis{1H-imidazole-5,2-diyl[(2S,4R)-4-fluoropyrrolidine-2,1-diyl][(1 S)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethane-2,1-diyl]}]biscarbamate, or

methyl [(1 S)-1-({(2S)-2-[5-(9-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-12-oxo-12H-benzo[a]xanthen-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}carbonyl)-2-methylpropyl]carbamate,

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

12. The pharmaceutical composition of claim 11 , further comprising a second antiviral agent.

13. The pharmaceutical composition of claim 12 , wherein the second antiviral agent is selected from an interferon, ribavirin, an interleukin, an NS3 protease inhibitor, a cysteine protease inhibitor, a phenathrenequinone, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a liotoxin, acerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, or a ribozyme.